Overview
Therapeutics Division aims to develop ‘Genomic Cure’ for incurable diseases. Based on CRISPR-Cas9 application and deep expertise of therapeutic development, we seek to provide novel solution for both genetic and non-genetic diseases.
By delivering CRISPR-Cas9 directly into the body with the help of clinically translatable delivery vehicles, we established in vivo therapeutic pipelines. On the other hand, by transferring CRISPR-Cas9 treated cells isolated from patients or healthy donors, we established ex vivo therapeutic pipelines.
Pipeline
In Vivo
TGT-001 | Charcot-Marie-Tooth Disease
PNS
Program(Disease)
In vitro POC
In vivo POC
Lead Optimization
Pre-Clinical
IND
Phase 1
TG-LBP | Hemophilia B
Liver
Program(Disease)
In vitro POC
In vivo POC
Lead Optimization
Pre-Clinical
IND
Phase 1
Ex Vivo
Next-generation CAR-T
Immune cell
Program(Disease)
In vitro POC
In vivo POC
Lead Optimization
Pre-Clinical
IND
Phase 1
CREAM
Engineered MSC
Program(Disease)
In vitro POC
In vivo POC
Lead Optimization
Pre-Clinical
IND
Phase 1